Compare Abbott Laboratories (ABT) vs ACADIA Pharmaceuticals Inc. (ACAD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs ACADIA Pharmaceuticals Inc. — how do they compare? Abbott Laboratories trades at $109.3 (market cap $187.95B), while ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B). The key difference: Abbott Laboratories is far larger — about 37.1× ACADIA Pharmaceuticals Inc.'s market cap, and Abbott Laboratories pays a 2.32% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ABT | ACAD | |
|---|---|---|
Market Cap | $187.95B | $5.07B |
Sector | Health | Health |
52-Week High | $136.62 | $29.41 |
52-Week Low | $82.57 | $20.06 |
Enterprise Value | $214.96B | $4.19B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →
